The stock price for Pacific Biosciences of California Inc (PACB) currently stands at $1.5. The stock experienced a substantial increase in the last session, hitting $3.0 after starting at $1.49. The stock’s lowest price was $1.25 before closing at $1.37.
Pacific Biosciences of California Inc experienced a somewhat shaky performance in the stock market.
52-week price history of PACB Stock
A stock’s 52-week high and low prices can reveal much about its current status and future trajectory. Pacific Biosciences of California Inc’s current trading price is -45.04% away from its 52-week high, while its distance from the 52-week low is 75.66%. The stock’s price range during this period has spanned from $0.85 to $2.72. In the Healthcare sector, the Pacific Biosciences of California Inc’s shares surpassed a trading volume of approximately 5.63 million for the day, which was noticeably lower compared to the average daily volume of 9.9.03 million over the past three months.
Market Capitalization and Financial Performance: An In-Depth Look
Pacific Biosciences of California Inc (PACB) has experienced a quarterly rise of 27.78% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 448.63M and boasts a workforce of 575 employees.
A Closer Look at Analysts’ Ratings for Pacific Biosciences of California Inc
As of right now, 5 analysts are rating Pacific Biosciences of California Inc as a BUY, 1 of the polled analysts branded the stock as an OVERWEIGHT, 7 analysts are recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
Making Sense of Trading Volume and Moving Average Data
Based on Barchart.com data, the company’s moving average over the 100-day period was 1.2337, with a change in price of -0.0464. Similarly, Pacific Biosciences of California Inc recorded 8,985,487 in trading volume during the last 100 days, posting a change of -2.97%.
Examining PACB’s Debt-to-Equity Ratio: What You Need to Know
The debt-to-equity (D/E) ratio is a crucial measure that sheds light on a company’s financial health and market standing. It is determined by dividing a company’s overall liabilities by its shareholders’ equity, showing the extent of a company’s debt usage in financing its assets compared to the shareholders’ equity. At the time of writing, the total D/E ratio for PACB stands at 7.63. Similarly, the long-term debt-to-equity ratio is also 7.60.
PACB Stock Stochastic Average
Today, Pacific Biosciences of California Inc’s raw stochastic average for the past 50 days stands at 84.00%, indicating a rise from the raw stochastic average of the last 20 days, which was 74.72%. Moreover, the company’s Stochastic %K and %D values over the past 20 days were 56.91% and 57.41% respectively.
PACB Stock Price Performance Analysis
The stock price performance for the year has been a mixed bag, indicating either a pessimistic or optimistic outlook depending on how you look at it. This year’s metric has recorded a Price decrease of -27.07%. However, over the past six months, we’ve seen a stronger performance of -6.56%. The price of PACB fallen by 14.12% over the last 30 days. And in the last five days, it has surged by 2.40%.
